Week In Review: Mabwell Bio Raises $547 Million In Shanghai STAR IPO

Mabwell Bioscience completed a $547 million IPO on Shanghai's STAR Board. Abbisko Therapeutics formed a global collaboration worth up to $258 million with Lilly to continue discovery and development of novel molecules for cardiometabolic diseases.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.